In conclusion, our study demonstrates that IL-22 is involved in the progression of AAA by regulating macrophage differentiation-related aortic oxidative stress and that IL-22 has potential as a clinical target for the prevention of AAA and AD. The gene discussed is IL22; the disease is triple-A syndrome.